Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;101(8):1627-1644.
doi: 10.1007/s00277-022-04872-1. Epub 2022 May 26.

Oncology stewardship in acute myeloid leukemia

Madeleine A Ochs  1 , Bernard L Marini  1   2 , Anthony J Perissinotti  1 , Charles E Foucar  3   4 , Kristen Pettit  3   4 , Patrick Burke  3   4 , Dale L Bixby  3   4 , Lydia L Benitez  5   6
Affiliations
Review

Oncology stewardship in acute myeloid leukemia

Madeleine A Ochs et al. Ann Hematol. 2022 Aug.

Abstract

In recent years, an explosion of novel agents has shifted the treatment paradigm for patients with acute myeloid leukemia. The optimal place in therapy for many of these novel agents remains unknown due to limited guidance from national guidelines and the way these agents were studied prior to entering the market. A critical evaluation of the literature and incorporation of oncology stewardship principles can be helpful in determining an optimal place for these agents while being mindful of the overall cost that is associated with therapies. The purpose of this review is to critically evaluate the efficacy and safety data for five controversial agents and provide examples of the use of stewardship practices in determining their place in the treatment of acute myeloid leukemia.

Keywords: Acute myeloid leukemia; Financial toxicity; Novel agents; Oncology stewardship.

PubMed Disclaimer

References

    1. Yates JW, Wallace HJ, Ellison RR, Holland JF (1973) Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 57(4):485–488 - PubMed
    1. National Cancer Institute Surveillance, Epidemiology, and End Results SEER) Program. Acute Myeloid Leukemia.: https://seer.cancer.gov/statfacts/html/amyl.html Accessed.
    1. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–59. https://doi.org/10.1056/NEJMoa061094 - DOI - PubMed
    1. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361(13):1249–1259. https://doi.org/10.1056/NEJMoa0904544 - DOI - PubMed - PMC
    1. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia Cancer and Leukemia Group B. N Engl J Med. 331(14):896–903. https://doi.org/10.1056/NEJM199410063311402 - DOI - PubMed

MeSH terms

LinkOut - more resources